JP2023535204A5 - - Google Patents

Info

Publication number
JP2023535204A5
JP2023535204A5 JP2023504633A JP2023504633A JP2023535204A5 JP 2023535204 A5 JP2023535204 A5 JP 2023535204A5 JP 2023504633 A JP2023504633 A JP 2023504633A JP 2023504633 A JP2023504633 A JP 2023504633A JP 2023535204 A5 JP2023535204 A5 JP 2023535204A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
infection
disease
pharmaceutically acceptable
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535204A (ja
Filing date
Publication date
Priority claimed from CN202010722697.9A external-priority patent/CN111686095A/zh
Application filed filed Critical
Publication of JP2023535204A publication Critical patent/JP2023535204A/ja
Publication of JP2023535204A5 publication Critical patent/JP2023535204A5/ja
Pending legal-status Critical Current

Links

JP2023504633A 2020-07-24 2021-07-19 コロナウイルス感染症の治療におけるカンナビジオールの応用 Pending JP2023535204A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010722697.9 2020-07-24
CN202010722697.9A CN111686095A (zh) 2020-07-24 2020-07-24 大麻二酚在制备治疗冠状病毒感染的药物中的用途
PCT/CN2021/107001 WO2022017304A1 (zh) 2020-07-24 2021-07-19 大麻二酚在治疗冠状病毒感染中的应用

Publications (2)

Publication Number Publication Date
JP2023535204A JP2023535204A (ja) 2023-08-16
JP2023535204A5 true JP2023535204A5 (https=) 2024-07-26

Family

ID=72486807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504633A Pending JP2023535204A (ja) 2020-07-24 2021-07-19 コロナウイルス感染症の治療におけるカンナビジオールの応用

Country Status (5)

Country Link
US (1) US20230263811A1 (https=)
EP (1) EP4186496B1 (https=)
JP (1) JP2023535204A (https=)
CN (2) CN120789031A (https=)
WO (1) WO2022017304A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4126913A4 (en) * 2020-03-29 2024-09-18 Akseera Pharma Corp. INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS FOR THE TREATMENT OF COVID-19
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途
KR102504114B1 (ko) 2020-09-29 2023-02-28 영남대학교 산학협력단 칸나비노이드를 유효성분으로 함유하는 중증 급성 호흡기 증후군 코로나 바이러스 2에 대한 항바이러스 조성물
CN115181791A (zh) * 2020-12-02 2022-10-14 飞象生物科技有限公司 一种筛选和识别具有抗病毒属性的小分子的方法
CN115177602A (zh) * 2021-04-06 2022-10-14 中国科学院微生物研究所 一种治疗结核病的药物
CN114732804A (zh) * 2022-03-15 2022-07-12 亨玛(浙江)生物科技有限公司 一种含大麻二酚cbd提取物在新型冠状病毒肺炎的应用
CN115778941A (zh) * 2022-11-18 2023-03-14 哈尔滨医科大学 一种抗新冠病毒联合用药物组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CN102924446B (zh) * 2011-08-11 2015-08-26 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
WO2020081634A2 (en) * 2018-10-16 2020-04-23 George Mason Research Foundation, Inc. Compositions and methods for modulation of extracellular vesicle release and treatment of neurological disorders
EP4126913A4 (en) * 2020-03-29 2024-09-18 Akseera Pharma Corp. INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS FOR THE TREATMENT OF COVID-19
US20230181484A1 (en) * 2020-05-11 2023-06-15 Add Advanced Drug Delivery Technologies Ltd. Uses and Formulations of Cannabinoids
WO2021228863A1 (en) * 2020-05-11 2021-11-18 Add Advanced Drug Delivery Technologies Ltd. Uses and formulations of cannabinoids
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Similar Documents

Publication Publication Date Title
JP2023535204A5 (https=)
Papich Papich handbook of veterinary Drugs-E-Book: Papich handbook of veterinary Drugs-E-Book
DK1982708T3 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanediol derivative as active ingredient and method of treating inflammatory bowel disease
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
JP2021523149A5 (https=)
EP3911317A2 (en) Methods of treating cartilage disorders through inhibition of clk and dyrk
CA2711807A1 (en) Agonists for antimicrobial peptide systems
JP6276944B2 (ja) フェキソフェナジンとｎｓａｉｄ含有医薬組成物
JP2022545156A5 (https=)
WO2012140504A1 (en) Therapeutic compounds
CN111407754A (zh) 卡谷氨酸在制备预防和治疗冠状病毒的药物中的应用
ES2816525T3 (es) Tratamiento de la coccidiosis con composiciones intramusculares de triazina
RS52737B (sr) Roscovitine za lečenje izvesnih cističnih bolesti
KR20070041561A (ko) 오심 및 구토의 치료에서의 치환된2-티오-3,5-디시아노-4-페닐-6-아미노피리딘의 용도
JP2005522418A5 (https=)
ES2365905T3 (es) Compuestos de tiofeno condensados y uso de los mismos en el tratamiento del dolor crónico.
WO2021202546A1 (en) Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death
RU2451514C1 (ru) Противовирусное средство в капсулах и способ его получения
CN104473932B (zh) 治疗中枢神经系统炎症性脱髓鞘疾病的药物组合物及其联合给药的用途
JP4829478B2 (ja) 医薬組成物
JP6178058B2 (ja) 抗炎症及び／又は抗ヒスタミン剤組成物
RU2446802C2 (ru) Противовирусное средство в таблетках и способ его получения
Uchendu et al. Chlorophyll Derivatives Exert Greater Potency Over Progesterone in the Prevention of Infection‐Induced Preterm Birth in Murine Models
Estienne et al. Effects of prostaglandins and prostaglandin synthesis inhibitors on sexual behavior in boars
ME01866B (me) Upotreba agomelatina za dobijanje ljekova namijenjenih liječenju periventrikularne leukomalacije